MUSC Health medical oncologist John M. Wrangle, M.D., discusses the National Cancer Institute trial, Molecular Analysis for Therapy Choice (NCIMATCH), which seeks to personalize treatment for patients with advanced cancer that has returned or worsened after standard systemic therapy. MUSC Hollings Cancer, an NCI-designated cancer center, is one of the sites for this study.
John M. Wrangle, M.D., is a board-certified medical oncologist. His clinical specialties include non-small cell lung cancer and small cell lung cancer. His medical degree was awarded by Tulane University School of Medicine. He completed ...
